Lv1
18 积分 2023-01-10 加入
Optimism Surrounds Claudin 18.2 ADC
1天前
已完结
Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial
1天前
已完结
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
3天前
已完结
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial
1个月前
已完结
HER2-targeted therapies beyond breast cancer — an update
1个月前
已完结
The potential of targeting TREM-1 in IBD
1个月前
已完结
The global burden of IBD: from 2015 to 2025
1个月前
已完结
The global burden of inflammatory bowel disease: from 2025 to 2045
1个月前
已完结
Recent discoveries on the acquisition of the highest levels of human performance
2个月前
已完结
Age and sex as key determinants of multiple sclerosis incidence in Spain: a comprehensive analysis using the global burden of disease database (1990–2019)
2个月前
已完结
皖公网安备34019202002308
